Tags: Drug.
SGN-CD33A is an antibody-drug conjugate (ADC) directed to CD33 designed for the treatment of Acute myeloid leukemia. It consists of a humanized anti-CD33 mAb with 2 engineered cysteine residues. The payloads are pyrrolobenzodiazepine (PBD) dimers which are conjugated with a maleimidocaproyl valine-alanine dipeptide linker. PBD dimers exert their biological activity by covalent binding and interstrand cross-linking of DNA.The drug is currently in phase I clinical trials for Acute myeloid leukemia